Previous experience with antiretroviral compounds has indicated that viral replication can be affected through the use of agents that target multiple steps in the HIV lifecycle. Even within the ...
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. That is the goal of an ...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...
(RTTNews) - Assembly Biosciences (ASMB), a biotechnology company focused on developing treatments for viral diseases, announced on Wednesday that the first participant has been dosed in its Phase 1a ...
Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback